<p>MacroGenics（纳斯达克股票代码：MGNX - 获取免费报告）于周一发布了季度财报。这家生物制药公司报告本季度每股收益为（$0.22），超出分析师一致预期的（$0.42）$0.20。该公司本季度的收入为 4123 万美元，而分析师的预期为 2781 万美元。MacroGenics 的净利润率为负的 59.46%，股本回报率为负的 98.30%。</p>
<h2>MacroGenics 股票上涨 22.8%</h2>
<p>周二，MacroGenics 的股票在交易时段上涨了$0.54，达到$2.90。该股票成交量为 1,011,313 股，而其平均成交量为 824,034 股。该公司的市值为 1.8333 亿美元，市盈率为-2.39，贝塔值为 1.45。公司 50 日移动平均价格为$1.80，200 日移动平均价格为$1.68。MacroGenics 的年内最低价为$0.99，年内最高价为$2.88。</p>
<h2>华尔街分析师预测增长</h2>
<p>MGNX 已成为多份分析师报告的主题。Zacks Research 在 1 月 1 日的报告中将 MacroGenics 的股票评级从 “强力买入” 下调至 “持有”。Weiss Ratings 在 12 月 22 日的研究报告中重申了对 MacroGenics 股票的 “卖出（d-）” 评级。最后，花旗集团在 2 月 24 日的研究报告中重申了对 MacroGenics 股票的 “市场表现” 评级。一位股票研究分析师给予该股票 “强力买入” 评级，一位给予 “买入” 评级，五位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为$3.60。</p>
<p><strong>查看我们关于 MacroGenics 的最新研究报告</strong></p>
<h2>对 MacroGenics 的对冲基金看法</h2>
<p>一些大型投资者最近对该公司的持仓进行了调整。Bridgeway Capital Management LLC 在第二季度将其在 MacroGenics 的持股增加了 16.1%。Bridgeway Capital Management LLC 现在拥有 133,700 股生物制药公司的股票，价值 162,000 美元，此前在上个季度购买了 18,500 股。Algert Global LLC 在第三季度购买了价值 148,000 美元的 MacroGenics 新股份。BNP Paribas Financial Markets 在第三季度将其在 MacroGenics 的持股增加了 87.9%。BNP Paribas Financial Markets 现在拥有 86,671 股生物制药公司的股票，价值 146,000 美元，此前在上个季度购买了 40,539 股。LPL Financial LLC 在第四季度将其在 MacroGenics 的持股增加了 181.2%。LPL Financial LLC 现在拥有 65,125 股生物制药公司的股票，价值 105,000 美元，此前在上个季度购买了 41,967 股。最后，Invesco Ltd.在第一季度将其在 MacroGenics 的持股增加了 90.0%。Invesco Ltd.现在拥有 68,377 股生物制药公司的股票，价值 87,000 美元，此前在上个季度购买了 32,398 股。96.89% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 MacroGenics</h2>
<p>（获取免费报告）</p>
<p>MacroGenics, Inc 是一家临床阶段的生物制药公司，专注于单克隆抗体基础治疗的发现和开发，旨在治疗癌症和自身免疫疾病。该公司利用专有的 Fc 工程技术来增强免疫参与并延长其抗体的活性。自 2000 年成立以来，MacroGenics 已将多个产品候选者推进临床试验，最著名的是 margetuximab，这是一种针对 HER2 的抗体，旨在改善 HER2 阳性乳腺癌患者的治疗效果。</p>
<p>MacroGenics 研究平台的核心是其 ADAPTIR 和 Trident 双特异性抗体技术。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 MacroGenics 更好</li>
<li>为什么这种稀有资源配置引起了早期关注</li>
<li>黄金的下一个上涨即将到来</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>美国的 1776 再次发生</li>
<li>在 2026 年 5 月 15 日之前购买这只黄金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdOWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 MacroGenics 吗？</h2>
<p>在考虑 MacroGenics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 MacroGenics 并不在名单上。</p>
<p>虽然 MacroGenics 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>MacroGenics（纳斯达克代码：MGNX）报告季度每股收益为（$0.22），超出预期的（$0.42）$0.20。公司实现收入为 4123 万美元，超过了 2781 万美元的预测。尽管股本回报率为负的 98.30% 和净利润率为 59.46%，但股价上涨了 22.8%，达到$2.90。分析师的评级意见不一，普遍评级为 “持有”，平均目标价为$3.60。机构投资者持有 96.89% 的股份，反映出对这家生物制药公司的强烈兴趣</p>

<p>MacroGenics (NASDAQ:MGNX - Get Free Report) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.20, reports. The business had revenue of $41.23 million for the quarter, compared to analysts' expectations of $27.81 million. MacroGenics had a negative net margin of 59.46% and a negative return on equity of 98.30%.</p>
<div class="lb-trans"><p>MacroGenics（纳斯达克股票代码：MGNX - 获取免费报告）于周一发布了季度财报。这家生物制药公司报告本季度每股收益为（$0.22），超出分析师一致预期的（$0.42）$0.20。该公司本季度的收入为 4123 万美元，而分析师的预期为 2781 万美元。MacroGenics 的净利润率为负的 59.46%，股本回报率为负的 98.30%。</p>
</div><h2>MacroGenics Stock Up 22.8%</h2>
<div class="lb-trans"><h2>MacroGenics 股票上涨 22.8%</h2>
</div><p>Shares of MacroGenics stock traded up $0.54 during trading hours on Tuesday, reaching $2.90. 1,011,313 shares of the stock traded hands, compared to its average volume of 824,034. The firm has a market capitalization of $183.33 million, a price-to-earnings ratio of -2.39 and a beta of 1.45. The company has a 50 day moving average price of $1.80 and a 200 day moving average price of $1.68. MacroGenics has a one year low of $0.99 and a one year high of $2.88.</p>
<div class="lb-trans"><p>周二，MacroGenics 的股票在交易时段上涨了$0.54，达到$2.90。该股票成交量为 1,011,313 股，而其平均成交量为 824,034 股。该公司的市值为 1.8333 亿美元，市盈率为-2.39，贝塔值为 1.45。公司 50 日移动平均价格为$1.80，200 日移动平均价格为$1.68。MacroGenics 的年内最低价为$0.99，年内最高价为$2.88。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>MGNX has been the topic of several analyst reports. Zacks Research cut shares of MacroGenics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, January 1st. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of MacroGenics in a research note on Monday, December 22nd. Finally, Citigroup reiterated a &#34;market perform&#34; rating on shares of MacroGenics in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and an average target price of $3.60.</p>
<div class="lb-trans"><p>MGNX 已成为多份分析师报告的主题。Zacks Research 在 1 月 1 日的报告中将 MacroGenics 的股票评级从 “强力买入” 下调至 “持有”。Weiss Ratings 在 12 月 22 日的研究报告中重申了对 MacroGenics 股票的 “卖出（d-）” 评级。最后，花旗集团在 2 月 24 日的研究报告中重申了对 MacroGenics 股票的 “市场表现” 评级。一位股票研究分析师给予该股票 “强力买入” 评级，一位给予 “买入” 评级，五位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为$3.60。</p>
</div><p><strong>View Our Latest Research Report on MacroGenics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MacroGenics 的最新研究报告</strong></p>
</div><h2>Hedge Funds Weigh In On MacroGenics</h2>
<div class="lb-trans"><h2>对 MacroGenics 的对冲基金看法</h2>
</div><p>A number of large investors have recently made changes to their positions in the business. Bridgeway Capital Management LLC grew its holdings in MacroGenics by 16.1% in the second quarter. Bridgeway Capital Management LLC now owns 133,700 shares of the biopharmaceutical company's stock valued at $162,000 after purchasing an additional 18,500 shares during the last quarter. Algert Global LLC bought a new stake in MacroGenics in the third quarter valued at $148,000. BNP Paribas Financial Markets raised its holdings in MacroGenics by 87.9% during the third quarter. BNP Paribas Financial Markets now owns 86,671 shares of the biopharmaceutical company's stock worth $146,000 after purchasing an additional 40,539 shares in the last quarter. LPL Financial LLC increased its stake in MacroGenics by 181.2% in the 4th quarter. LPL Financial LLC now owns 65,125 shares of the biopharmaceutical company's stock worth $105,000 after purchasing an additional 41,967 shares in the last quarter. Finally, Invesco Ltd. grew its position in MacroGenics by 90.0% during the first quarter. Invesco Ltd. now owns 68,377 shares of the biopharmaceutical company's stock valued at $87,000 after purchasing an additional 32,398 shares in the last quarter. 96.89% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近对该公司的持仓进行了调整。Bridgeway Capital Management LLC 在第二季度将其在 MacroGenics 的持股增加了 16.1%。Bridgeway Capital Management LLC 现在拥有 133,700 股生物制药公司的股票，价值 162,000 美元，此前在上个季度购买了 18,500 股。Algert Global LLC 在第三季度购买了价值 148,000 美元的 MacroGenics 新股份。BNP Paribas Financial Markets 在第三季度将其在 MacroGenics 的持股增加了 87.9%。BNP Paribas Financial Markets 现在拥有 86,671 股生物制药公司的股票，价值 146,000 美元，此前在上个季度购买了 40,539 股。LPL Financial LLC 在第四季度将其在 MacroGenics 的持股增加了 181.2%。LPL Financial LLC 现在拥有 65,125 股生物制药公司的股票，价值 105,000 美元，此前在上个季度购买了 41,967 股。最后，Invesco Ltd.在第一季度将其在 MacroGenics 的持股增加了 90.0%。Invesco Ltd.现在拥有 68,377 股生物制药公司的股票，价值 87,000 美元，此前在上个季度购买了 32,398 股。96.89% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About MacroGenics</h2>
<div class="lb-trans"><h2>关于 MacroGenics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.</p>
<div class="lb-trans"><p>MacroGenics, Inc 是一家临床阶段的生物制药公司，专注于单克隆抗体基础治疗的发现和开发，旨在治疗癌症和自身免疫疾病。该公司利用专有的 Fc 工程技术来增强免疫参与并延长其抗体的活性。自 2000 年成立以来，MacroGenics 已将多个产品候选者推进临床试验，最著名的是 margetuximab，这是一种针对 HER2 的抗体，旨在改善 HER2 阳性乳腺癌患者的治疗效果。</p>
</div><p>Central to MacroGenics' research platform are its ADAPTIR and Trident bispecific antibody technologies.</p>
<div class="lb-trans"><p>MacroGenics 研究平台的核心是其 ADAPTIR 和 Trident 双特异性抗体技术。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than MacroGenics</li>
<li>Why this rare resource setup is catching early attention</li>
<li>Gold's Next Surge is Imminent</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 15th, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 MacroGenics 更好</li>
<li>为什么这种稀有资源配置引起了早期关注</li>
<li>黄金的下一个上涨即将到来</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>美国的 1776 再次发生</li>
<li>在 2026 年 5 月 15 日之前购买这只黄金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUdOWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=MGNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MacroGenics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 MacroGenics 吗？</h2>
</div><p>Before you consider MacroGenics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MacroGenics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 MacroGenics 并不在名单上。</p>
</div><p>While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MacroGenics 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Market Beat

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

标普全球医疗股指数 ETF - iShares

标普生物技术 3 倍做空 - Direxion

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

Macrogenics

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

MacroGenics（纳斯达克代码：MGNX）公布季度财报，每股收益比预期高出 0.20 美元